Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Thursday, Marketbeat.com reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 40.37% from the stock’s previous close.

A number of other brokerages have also weighed in on ORKA. Guggenheim reiterated a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Trading Down 4.9%

Shares of ORKA traded down $4.44 during mid-day trading on Thursday, reaching $85.49. The company had a trading volume of 1,292,493 shares, compared to its average volume of 1,102,719. The stock has a market cap of $5.66 billion, a price-to-earnings ratio of -42.11 and a beta of -0.34. The firm has a fifty day simple moving average of $96.79 and a 200-day simple moving average of $75.32. Oruka Therapeutics has a fifty-two week low of $14.89 and a fifty-two week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities analysts predict that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at $84,996,011.40. The trade was a 7.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at $1,633,177.92. The trade was a 39.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 122,950 shares of company stock worth $11,528,806 in the last quarter. 23.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $474,916,000. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $130,968,000. Remedium Capital Partners LLC grew its position in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Oruka Therapeutics by 16.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock valued at $44,753,000 after buying an additional 208,480 shares during the last quarter. Finally, Avidity Partners Management LP grew its position in shares of Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after buying an additional 100,000 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Oruka reported that its ORKA-001 psoriasis therapy produced deeper responses through Week 28 in the Phase 2a EVERLAST-A trial without additional dosing. PASI 100 increased to 71.4% and PASI 90 to 87.3%, while patients who crossed over from placebo achieved similar response rates. The company said ORKA-001 maintained a favorable safety and tolerability profile. Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001
• Positive Sentiment: UBS described ORKA-001’s psoriasis treatment profile as competitive following the new clinical data, supporting the potential for durable efficacy and reinforcing investor interest in Oruka’s pipeline. Oruka Therapeutics Psoriasis Treatment Maintains Competitive Profile
• Positive Sentiment: Analysts remain bullish: Wedbush reaffirmed an Outperform rating with a $165 price target, while HC Wainwright reiterated Buy with a $120 target. Other coverage also highlights Oruka among attractive healthcare stocks. Analysts Are Bullish on Oruka Therapeutics
• Neutral Sentiment: Oruka also provided progress on the randomized, double-blind, placebo-controlled ORKA-002 study in hidradenitis suppurativa. The update expands the pipeline opportunity, but the study remains clinical-stage and does not yet establish efficacy. ORKA-002 Trial Progress
• Negative Sentiment: The stock fell after the psoriasis update even though efficacy improved. Reports indicate that safety disclosures may have offset the positive results, while investors may also be taking profits or demanding more complete data. Full 52-week EVERLAST-A results are expected in December 2026, leaving additional clinical risk ahead. ORKA Stock Down Despite Positive Week 28 Data

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.